These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 7528179)

  • 21. [Tadenan treatment of prostatic adenoma].
    Danilov VV; Elisseva EV; Vasil'chenko AV
    Urologiia; 2009; (2):68, 70-3. PubMed ID: 19526878
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bipolar plasma enucleation of the prostate vs open prostatectomy in large benign prostatic hyperplasia cases - a medium term, prospective, randomized comparison.
    Geavlete B; Stanescu F; Iacoboaie C; Geavlete P
    BJU Int; 2013 May; 111(5):793-803. PubMed ID: 23469933
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of an anti-androgen, SH 714 (6-chlor-delta-6-1, 2-alpha-methylen-17-alpha-hydroxyprogesterone acetate, cyproterone acetate) on canine prostatic hyperplasia.
    Neri RO; Casmer C; Zeman WV; Fielder F; Tabachnick II
    Endocrinology; 1968 Feb; 82(2):311-7. PubMed ID: 4170420
    [No Abstract]   [Full Text] [Related]  

  • 24. [Giant prostatic hyperplasia: a case report and review of the literature].
    Huang K; He LY
    Zhonghua Nan Ke Xue; 2011 Feb; 17(2):151-5. PubMed ID: 21404714
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transurethral enucleation and resection of the prostate vs transvesical prostatectomy for prostate volumes >80 mL: a prospective randomized study.
    Ou R; Deng X; Yang W; Wei X; Chen H; Xie K
    BJU Int; 2013 Jul; 112(2):239-45. PubMed ID: 23795788
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Dysuria following transurethral electroresections of adenomas with concomitant prostatitis].
    Hak-Hagir A
    Urologe A; 1985 Mar; 24(2):122-3. PubMed ID: 2581356
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical overview of prazosin in the treatment of prostatic obstruction.
    Milroy E
    Urol Int; 1990; 45 Suppl 1():1-3. PubMed ID: 1690474
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Correlations between parameters in uroflowmetry and histological compositions in patients with benign prostatic hyperplasia.
    Ishigooka M; Hayami S; Hashimoto T; Suzuki Y; Sasagawa I; Nakada T
    Urol Int; 1996; 57(1):48-50. PubMed ID: 8840491
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Plasmakinetic enucleation of the prostate versus transvesical open prostatectomy for benign prostatic hyperplasia >80 mL: 12-month follow-up results of a randomized clinical trial.
    Rao JM; Yang JR; Ren YX; He J; Ding P; Yang JH
    Urology; 2013 Jul; 82(1):176-81. PubMed ID: 23601443
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The importance of prostatic measuring by transrectal ultrasound in surgical management of patients with clinically benign prostatic hyperplasia.
    Milonas D; Trumbeckas D; Juska P
    Medicina (Kaunas); 2003; 39(9):860-6. PubMed ID: 14515048
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative study of selective alpha 1-adrenoceptor blockade versus surgery in the treatment of prostatic obstruction.
    Chapple CR; Noble JG; Milroy EJ
    Br J Urol; 1993 Nov; 72(5 Pt 2):822-5. PubMed ID: 7506628
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Quantitative morphometry of hyperplastic hypoechoic nodules in the prostatic outer gland].
    Li X; Wang N; Shi HY; Zhang Y; Fu XS; Li JL; Xu JH; Tang J
    Zhonghua Nan Ke Xue; 2005 Feb; 11(2):91-3. PubMed ID: 15755023
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of Difaprost® on voiding dysfunction, histology and inflammation markers in patients with benign prostatic hyperplasia who are candidates for surgical treatment.
    Suardi N; Gandaglia G; Nini A; Montorsi F; Pellucchi F; Agostini A; Rigatti P
    Minerva Urol Nefrol; 2014 Jun; 66(2):119-25. PubMed ID: 24988203
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of oral Tadenan treatment on rabbit bladder structure and function after partial outlet obstruction.
    Levin RM; Hass MA; Bellamy F; Horan P; Whitbeck K; Chow PH; Kung LS; Gosling J
    J Urol; 2002 May; 167(5):2253-9. PubMed ID: 11956488
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Does induction of apoptosis contribute to the overall clinical profile of terazosin? Introduction.
    Bartsch G
    Prostate Suppl; 2000; 9():2-3. PubMed ID: 11056495
    [No Abstract]   [Full Text] [Related]  

  • 36. Age-related changes of histological composition in established benign prostatic hyperplasia.
    Ishigooka M; Hayami S; Suzuki Y; Hashimoto T; Sasagawa I; Nakada T
    Eur Urol; 1996; 29(1):85-9. PubMed ID: 8821697
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical relevance of growth factor antagonists in the treatment of benign prostatic hyperplasia.
    Desgrandchamps F
    Eur Urol; 1997; 32 Suppl 1():28-31. PubMed ID: 9218940
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Histopathology of benign prostatic hyperplasia after failure of hyperthermia treatment.
    Siegel YI; Zaidel L; Hammel I; Korczak D; Lindner A
    Br J Urol; 1991 Oct; 68(4):383-6. PubMed ID: 1718527
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical perspective on apoptosis in the management of the BPH patient.
    Fitzpatrick J
    Prostate Suppl; 2000; 9():47-50. PubMed ID: 11056503
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Re: Rubiao et al.: A randomized trial of transvesical prostatectomy versus transurethral resection of the prostate for prostate greater than 80 mL (Urology 2010;76;958-961).
    Shenoy SP; Marla PK; Adappa KK
    Urology; 2011 Mar; 77(3):764; author reply 764-5. PubMed ID: 21377023
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.